NFATC2 and neoplasm: The original report comparing CIC-DUX4 and EWSR1-NFATc2 positive tumors identified key molecular markers differentiating the two diseases; presenting PAX7 as a highly specific marker for EWSR1-NFATc2 positive tumor diagnosis.